CRISPR Stock Today

CRSP -  USA Stock  

USD 54.71  1.63  2.89%

Market Performance
2 of 100
Odds Of Distress
Less than 2
CRISPR Therapeutics is selling at 54.71 as of the 24th of May 2022; that is -2.89 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 53.96. CRISPR Therapeutics has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for CRISPR Therapeutics AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2020 and ending today, the 24th of May 2022. Click here to learn more.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. The company has 76.53 M outstanding shares of which 10.14 M shares are currently shorted by private and institutional investors with about 9.06 trading days to cover. More on CRISPR Therapeutics AG
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

CRISPR Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. CRISPR Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding CRISPR Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CRISPR Therapeutics has very high historical volatility over the last 90 days
About 63.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.nasdaq.com: CRISPR Therapeutics AG Shares Close the Week 21.4 percent Higher - Weekly Wrap - Nasdaq
CRISPR Therapeutics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
CRISPR Therapeutics SEC Filings
CRISPR Therapeutics SEC Filings Security & Exchange Commission EDGAR Reports
CEO, Co-Founder, DirectorRodger Novak  (View All)
Average Analyst Recommendation
Analysts covering CRISPR Therapeutics report their recommendations after researching CRISPR Therapeutics' financial statements, talking to executives and customers, or listening in on CRISPR Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering CRISPR Therapeutics. The CRISPR consensus assessment is calculated by taking the average forecast from all of the analysts covering CRISPR Therapeutics.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of CRISPR Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of CRISPR Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 6 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares62.1 M75.9 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted64.9 M80.4 M
Significantly Down
Increasing
Slightly volatile
Net Cash Flow from Operations581.5 M539 M
Significantly Up
Increasing
Slightly volatile
Total AssetsB2.8 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities380.2 M352.4 M
Significantly Up
Increasing
Slightly volatile
Current Assets2.6 B2.4 B
Significantly Up
Increasing
Slightly volatile
Current Liabilities129.3 M119.9 M
Significantly Up
Increasing
Slightly volatile
Total Debt242.8 M225 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets0.160.145
Significantly Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.380.351
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of CRISPR Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
CRISPR Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to CRISPR Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CRISPR Therapeutics' financial leverage. It provides some insight into what part of CRISPR Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on CRISPR Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how CRISPR Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
CRISPR Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 225.03 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. CRISPR Therapeutics has a current ratio of 19.77, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist CRISPR Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, CRISPR Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CRISPR Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CRISPR to invest in growth at high rates of return. When we think about CRISPR Therapeutics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

581.52 MillionShare
CRISPR Therapeutics AG (CRSP) is traded on NASDAQ Exchange in USA. It is located in Baarerstrasse 14 and employs 473 people. CRISPR Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 4.31 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CRISPR Therapeutics's market, we take the total number of its shares issued and multiply it by CRISPR Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. CRISPR Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 76.53 M outstanding shares of which 10.14 M shares are currently shorted by private and institutional investors with about 9.06 trading days to cover. CRISPR Therapeutics AG currently holds about 2.38 B in cash with 538.97 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 30.87.
Check CRISPR Therapeutics Probability Of Bankruptcy
Ownership
CRISPR Therapeutics retains a total of 76.53 Million outstanding shares. Over half of CRISPR Therapeutics outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Thus, these institutions are subject to different rules and regulation than regular investors in CRISPR Therapeutics. Please watch out for any change in the institutional holdings of CRISPR Therapeutics as this could mean something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check CRISPR Ownership Details

CRISPR Stock Price Odds Analysis

What are CRISPR Therapeutics' target price odds to finish over the current price? Contingent on a normal probability distribution, the odds of CRISPR Therapeutics jumping above the current price in 90 days from now is about 71.76%. The CRISPR Therapeutics AG probability density function shows the probability of CRISPR Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.6918 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, CRISPR Therapeutics will likely underperform. Additionally, the company has an alpha of 0.1904, implying that it can generate a 0.19 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 54.71HorizonTargetOdds Above 54.71
28.12%90 days
 54.71 
71.76%
Based on a normal probability distribution, the odds of CRISPR Therapeutics to move above the current price in 90 days from now is about 71.76 (This CRISPR Therapeutics AG probability density function shows the probability of CRISPR Stock to fall within a particular range of prices over 90 days) .

CRISPR Stock Institutional Holders

Institutional Holdings refers to the ownership stake in CRISPR Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CRISPR Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CRISPR Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Ark Investment Management LlcCommon Shares9.4 M590.3 M
Nea Management Company LlcCommon Shares1.6 M365.6 M
View CRISPR Therapeutics Diagnostics

CRISPR Therapeutics Historical Income Statement

CRISPR Therapeutics AG Income Statement is one of the three primary financial statements used for reporting CRISPR's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of CRISPR Therapeutics revenue and expense. CRISPR Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
CRISPR Therapeutics Operating Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Operating Income of 373.53 Million. As of 24th of May 2022, Revenues is likely to grow to about 987.2 M, while Weighted Average Shares is likely to drop about 62.1 M. View More Fundamentals

CRISPR Stock Against Markets

Picking the right benchmark for CRISPR Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in CRISPR Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for CRISPR Therapeutics is critical whether you are bullish or bearish towards CRISPR Therapeutics AG at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

CRISPR Therapeutics Corporate Directors

CRISPR Therapeutics corporate directors refer to members of a CRISPR Therapeutics board of directors. The board of directors generally takes responsibility for the CRISPR Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of CRISPR Therapeutics' board members must vote for the resolution. The CRISPR Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Simeon George - Independent DirectorProfile
Ali Behbahani - Independent DirectorProfile
Bradley Bolzon - Independent DirectorProfile
Jim Kasinger - General Counsel, Secretary to the Board of DirectorsProfile

Investing CRISPR Therapeutics AG

You need to understand the risk of investing before taking a position in CRISPR Therapeutics. The danger of trading CRISPR Therapeutics AG is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of CRISPR Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than CRISPR Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile CRISPR Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.